Niranjan Narasimhan, DJ Dorer, K. Niland
Jul 25, 2013
Citations
1
Influential Citations
34
Citations
Quality indicators
Journal
Journal of Clinical Pharmacy and Therapeutics
Abstract
Ponatinib is a potent oral tyrosine kinase inhibitor with activity against BCR‐ABL, the primary driver of chronic myeloid leukaemia and Philadelphia chromosome–positive acute lymphoblastic leukaemia. This single‐centre, single‐dose, randomized, open‐label, three‐period crossover study evaluated the pharmacokinetics and bioavailability of a single oral dose of ponatinib (45‐mg tablet) under fasting conditions and following consumption of high‐ and low‐fat meals by healthy subjects.